Company intelligence / Profile preview
KiraGen Bio
Allston, Massachusetts, United Stateskiragenbio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
KiraGen Bio is developing AI-driven, multiplex gene-edited CAR-T cell therapies for solid tumors. The company engineers CAR-T cells with up to 8 tumor microenvironment resistance gene edits to overcome immunosuppression[6].
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapiesmultiplex gene-edited cell therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Flash BioSolutions (announced April 2, 2024)[6]
Beyond the preview
Go deeper on KiraGen Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KiraGen Bio.